Eli Lilly Sues 4 GLP-1 Telehealth Startups, Escalating War on Knockoff Drugs

The conflict between the drug industry and healthcare providers over GLP-1 medications has reached a new high as Eli Lilly sues four telehealth companies for selling unapproved off-label versions of its drugs, Mounjaro and Zepbound, which collectively brought in $16.4 billion last year. These compounded medications, often cheaper but not FDA-approved, have gained popularity due to recent shortages, allowing affordable treatments to reach millions through telehealth platforms. --- This summary captures the essence of the article with a clear structure, starting with the conflict and moving into how off-label treatments became popular and their impact on telehealth companies.